EE200000589A - Kiirlahustuvate efavirenskapslite või -tablettideformuleerimine kasutades superlagundeid - Google Patents

Kiirlahustuvate efavirenskapslite või -tablettideformuleerimine kasutades superlagundeid

Info

Publication number
EE200000589A
EE200000589A EEP200000589A EEP200000589A EE200000589A EE 200000589 A EE200000589 A EE 200000589A EE P200000589 A EEP200000589 A EE P200000589A EE P200000589 A EEP200000589 A EE P200000589A EE 200000589 A EE200000589 A EE 200000589A
Authority
EE
Estonia
Prior art keywords
supernatants
tablets
formulation
instant soluble
efavirenz
Prior art date
Application number
EEP200000589A
Other languages
English (en)
Inventor
T. Makooi-Morehead William
D. Buehler John
R. Landmann Brian
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000589A publication Critical patent/EE200000589A/et
Publication of EE04391B1 publication Critical patent/EE04391B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000589A 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid EE04391B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
EE200000589A true EE200000589A (et) 2002-04-15
EE04391B1 EE04391B1 (et) 2004-12-15

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000589A EE04391B1 (et) 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Country Status (27)

Country Link
US (2) US6238695B1 (et)
EP (1) EP1067936B1 (et)
JP (1) JP2002510634A (et)
KR (1) KR100634253B1 (et)
CN (1) CN1146419C (et)
AR (1) AR019031A1 (et)
AT (1) ATE223719T1 (et)
AU (1) AU756422B2 (et)
BR (1) BR9908810A (et)
CA (1) CA2321523C (et)
CZ (1) CZ300850B6 (et)
DE (1) DE69902893T2 (et)
DK (1) DK1067936T3 (et)
EA (1) EA003217B1 (et)
EE (1) EE04391B1 (et)
ES (1) ES2181417T3 (et)
HU (1) HU228498B1 (et)
IL (1) IL138078A (et)
NO (1) NO325824B1 (et)
NZ (1) NZ507566A (et)
PL (1) PL194309B1 (et)
PT (1) PT1067936E (et)
SK (1) SK284655B6 (et)
TW (1) TW576741B (et)
UA (1) UA72207C2 (et)
WO (1) WO1999051239A1 (et)
ZA (1) ZA200004313B (et)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
DK1083885T3 (da) * 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
MXPA05007016A (es) * 2003-01-14 2005-09-12 Gilead Sciences Inc Composiciones y metodos para terapia antiviral de combinacion.
US8021682B2 (en) 2004-08-13 2011-09-20 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008033487A2 (en) * 2006-09-14 2008-03-20 Chemlink Laboratories Llc Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
WO2011131943A2 (en) * 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical compositions
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
IN2013MU03370A (et) 2013-10-25 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880701098A (ko) 1986-04-01 1988-07-25 로버어트 에이 아미테이지 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
HU205717B (en) * 1989-04-28 1992-06-29 Daiichi Seiyaku Co Process for producing pharmaceutical composition against human immunodeficiency, comprising pyridionecarboxylic acid derivative
EP0577913B1 (en) * 1992-07-08 1997-06-18 Leiras Oy Ophthalmic composition containing timolol hemihydrate
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas

Also Published As

Publication number Publication date
NO20005043L (no) 2000-10-06
DK1067936T3 (da) 2003-02-17
EE04391B1 (et) 2004-12-15
ZA200004313B (en) 2002-01-30
CN1146419C (zh) 2004-04-21
EP1067936B1 (en) 2002-09-11
AU756422B2 (en) 2003-01-09
PL343421A1 (en) 2001-08-13
HUP0101517A3 (en) 2002-11-28
NO325824B1 (no) 2008-07-21
HU228498B1 (en) 2013-03-28
NZ507566A (en) 2002-11-26
ATE223719T1 (de) 2002-09-15
SK284655B6 (sk) 2005-08-04
JP2002510634A (ja) 2002-04-09
DE69902893D1 (de) 2002-10-17
CN1296412A (zh) 2001-05-23
CA2321523C (en) 2008-10-07
WO1999051239A1 (en) 1999-10-14
DE69902893T2 (de) 2003-04-30
ES2181417T3 (es) 2003-02-16
PT1067936E (pt) 2002-12-31
CA2321523A1 (en) 1999-10-14
NO20005043D0 (no) 2000-10-06
AR019031A1 (es) 2001-12-26
IL138078A0 (en) 2001-10-31
AU3463799A (en) 1999-10-25
CZ300850B6 (cs) 2009-08-26
EA003217B1 (ru) 2003-02-27
CZ20003571A3 (cs) 2001-01-17
SK14612000A3 (sk) 2001-07-10
US6555133B2 (en) 2003-04-29
EP1067936A1 (en) 2001-01-17
IL138078A (en) 2005-12-18
HUP0101517A2 (hu) 2001-11-28
EA200001030A1 (ru) 2001-04-23
KR20010042473A (ko) 2001-05-25
US20010012518A1 (en) 2001-08-09
US6238695B1 (en) 2001-05-29
UA72207C2 (uk) 2005-02-15
BR9908810A (pt) 2000-12-19
PL194309B1 (pl) 2007-05-31
TW576741B (en) 2004-02-21
KR100634253B1 (ko) 2006-10-16

Similar Documents

Publication Publication Date Title
EE200000589A (et) Kiirlahustuvate efavirenskapslite või -tablettideformuleerimine kasutades superlagundeid
ATE228823T1 (de) Pharmazeutische aerosolformulierung
EG24044A (en) pharmaceutical formulation of omeprazole
IS5524A (is) Forðatöflur til inntöku
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IS4360A (is) Lyfjablanda í skammtaformi til munninntöku
NO992339D0 (no) Farmas°ytiske formuleringer
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
NO20012915D0 (no) Ny farmasöytisk formulering
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
DE59915033D1 (de) Pharmazeutische Zubereitung
DK0868911T3 (da) Rapamycinpræparater til oral indgivelse
ID30032A (id) Formulasi farmasi
ATE295150T1 (de) Pharmazeutische zusammensetzungen
DK0994697T3 (da) Rapamycinformuleringer til oral indgivelse
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20024354L (no) N-deacetyltiocolchicin-derivater og farmasöytiske sammensetninger inneholdende dem
NO20002114L (no) Bisykliske forbindelser, fremgangsmÕte for deres fremstilling og farmasøytiske sammensetninger inneholdende dem
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
SE9803952D0 (sv) Pharmaceutical formulation
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231